The review, conducted by a team of researchers led by Abhinav Janappareddi of the University of Washington School of Medicine, systematically combed the medical literature through PubMed and Scopus to identify every study that had reported outcomes for hidradenocarcinoma treated with Mohs micrographic surgery. The search identified seven studies published between 2004 and 2021, and from those studies the team extracted eighteen documented cases in which patients with hidradenocarcinoma underwent the Mohs procedure. The headline finding is striking: across all eighteen cases, the authors found no reported recurrences and no reported metastases during follow-up.

To appreciate why that number matters, it helps to understand what the conventional alternative achieves. Wide local excision, the most commonly reported treatment for hidradenocarcinoma, removes the visible tumor together with a predetermined margin of surrounding tissue, typically several centimeters in every direction. The excised specimen is then examined by a pathologist, who checks whether the margins are free of tumor. Recurrence rates for hidradenocarcinoma treated this way range from 10 to 50 percent in the published literature, a spread that reflects both the biology of the tumor and the difficulty of ensuring that invisible fingerlike extensions of cancer have been completely removed.

Mohs micrographic surgery takes the opposite approach to margin control. Instead of removing a fixed block of tissue and waiting for pathology results, the Mohs surgeon removes the tumor in thin layers. Each layer is immediately frozen, sectioned, stained, and examined under the microscope while the patient waits in the office. The microscope is used to map exactly where tumor cells remain, and only those specific areas are excised in the next layer. The process repeats until every margin is microscopically clear. The result is a surgical technique that achieves complete margin assessment, rather than the sampling assessment that conventional pathology provides, while sparing as much healthy tissue as possible.

That tissue-sparing quality is particularly valuable for hidradenocarcinoma because of where these tumors tend to appear. The review notes that cases have arisen on the scalp, the forehead, the nose, the vulva, and the abdominal wall, sites where wide excision can be disfiguring or technically challenging. One of the studies included in the review described the challenge of treating hidradenocarcinoma on a rhinophymatous nose, where distorted anatomy made histologic interpretation genuinely difficult, a situation the authors of that report called a histologic conundrum. Another described a multidisciplinary approach combining Mohs surgery with other specialties to manage a hidradenocarcinoma of the scalp. In each of these scenarios, the ability to trace tumor extensions microscopically, layer by layer, offers a rational advantage over removing a large fixed margin and hoping it was enough.

The biology of hidradenocarcinoma helps explain why margin control is so critical. The tumor is known by several names in the literature, including malignant hidradenoma, malignant acrospiroma, clear cell eccrine carcinoma, and primary mucoepidermoid cutaneous carcinoma, reflecting a long history of debate about its exact classification. What unites these labels is that the tumor arises from the eccrine or apocrine sweat duct apparatus and behaves with a propensity for local infiltration and, in a meaningful minority of cases, metastasis to lymph nodes and distant organs. Reported cases in the broader literature describe patients requiring surgery combined with chemotherapy for metastatic disease, or wide excision plus adjuvant radiotherapy for tumors of the trunk. Against that backdrop, a surgical series with zero recurrences is not a trivial statistical curiosity but a signal worth investigating.

The authors of the review are careful, appropriately, not to overclaim. Eighteen cases spread across seven studies is a small foundation, and the studies themselves are largely case reports and small case series, the weakest tier of the clinical evidence hierarchy. Patients were not randomized to Mohs surgery versus wide local excision, follow-up durations varied, and publication bias likely favors the reporting of successful outcomes. The authors explicitly state that the generalizability of current findings is limited by the existing literature, and they frame their result not as a practice-changing conclusion but as a call for larger, controlled studies to better define the role of Mohs micrographic surgery in hidradenocarcinoma management, whether as a sole treatment or in combination with adjunct therapies such as sentinel lymph node mapping or radiotherapy.

That caution is consistent with how the field has historically handled ultra-rare tumors. When a cancer is so uncommon that no single institution can accumulate a meaningful series, the evidence base is built case by case, and narrative reviews like this one serve as the mechanism for aggregating scattered experience into something approaching a signal. The Mayo Clinic experience included in the review, covering Mohs treatment of hidradenocarcinoma from 1993 to 2013, represents one of the largest single-institution contributions, and even it contributed only a handful of cases. A more recent case series from Scripps Clinic, published in 2024, similarly combined institutional experience with a systematic review of the literature, underscoring how slowly the evidence accumulates for a tumor that most dermatologists may see once, if ever, in a career.

For clinicians, the practical takeaway is nuanced. Wide local excision remains the most commonly reported and most widely accepted treatment, and no guideline currently recommends replacing it with Mohs surgery on the strength of eighteen cases. But the review gives surgeons treating a hidradenocarcinoma in a cosmetically or functionally sensitive location, such as the face, scalp, or genital skin, a documented body of experience supporting Mohs micrographic surgery as a reasonable alternative, particularly when the goal is complete microscopic margin control without sacrificing large amounts of tissue. It also reinforces the importance of long-term surveillance regardless of the surgical approach, because even the most optimistic case series cannot yet rule out late recurrences or metastases.

For patients, the message is one of cautious optimism. A cancer that has historically recurred in as many as half of treated cases may, in the documented experience of Mohs surgery to date, have been cured in every reported instance. That gap between 10 to 50 percent recurrence and zero recurrences is exactly the kind of discrepancy that motivates the larger, controlled studies the authors are calling for. Until those studies exist, the eighteen patients whose outcomes form the backbone of this review represent both the best evidence available and a compelling argument that the microscope, used layer by layer in the operating room, may deserve a larger role in the fight against one of dermatology’s rarest and most feared tumors.

Subject of Research: Treatment of hidradenocarcinoma with Mohs micrographic surgery

Article Title: Hidradenocarcinoma: a narrative review of treatment with Mohs micrographic surgery

Article References: Janappareddi, A., Kamineni, D. P., Kaur, P., Collins, C. L., Almatroud, L., Verzosa, M. S., Oh, A., Sanka, S. A., Kooner, A., Wan, L., Bondugula, N., & Engledow, E. (2026). Hidradenocarcinoma: a narrative review of treatment with Mohs micrographic surgery. Archives of Dermatological Research, 318(1), Article 466. https://doi.org/10.1007/s00403-026-04955-3

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04955-3

Keywords: hidradenocarcinoma, Mohs micrographic surgery, wide local excision, sweat gland cancer, eccrine carcinoma, dermatologic surgery, cancer recurrence, skin cancer, narrative review, adjuvant therapy, dermatology, malignant acrospiroma

The study, published as a short report in the Archives of Dermatological Research, examined patients with stage T1a and T1b melanomas—lesions that are, by definition, thin and caught early—who were treated with Mohs micrographic surgery between 2008 and 2018 at a single tertiary care academic institution. The researchers combed patient charts to record three key variables for each case: the initial margin used when Mohs surgery began, whether the melanoma recurred, and whether the patient ultimately died of melanoma. Statistical analysis then tested whether the width of the starting margin influenced the risk of dying from the disease. The answer, according to the data, was no.

Only two of the 326 patients died from melanoma during the follow-up period, and both of those patients had received relatively generous initial margins of 8 millimeters and 10 millimeters respectively. That detail is striking because it runs counter to the intuitive logic that wider margins should offer greater protection. With such a small number of events, the study cannot definitively prove that margin size is irrelevant to survival, but the near-total absence of melanoma deaths across a decade of patients—regardless of whether surgeons started with margins smaller or larger than one centimeter—adds to a growing body of evidence that the initial margin in Mohs surgery is not a critical determinant of survival outcomes.

To understand why this finding is significant, it helps to consider what makes Mohs micrographic surgery fundamentally different from a conventional wide local excision. In a standard excision, the surgeon removes the tumor along with a predetermined cuff of healthy-appearing skin, and the specimen is sent to a pathology laboratory where tissue is sampled at intervals—often through vertical sectioning that examines only a small fraction of the true margin. If malignant cells remain at the surgical edge, they may escape detection. Mohs surgery, by contrast, is built around complete margin control. The surgeon removes the visible tumor with a thin initial layer, then processes that tissue so that 100 percent of the peripheral and deep margins can be examined under the microscope while the patient waits. If cancer cells are identified anywhere along the margin, the surgeon maps their location and removes another thin layer precisely where the disease persists, repeating the process until the margins are entirely clear.

It is this exhaustive margin evaluation, the study’s authors argue, that likely explains why the initial margin width does not influence melanoma-specific mortality. When the first excision is narrow and tumor extends beyond it, the Mohs technique detects and removes those residual cells in subsequent stages. When the first excision is wide, fewer stages may be needed, but the final result—histologically clear margins—is the same. In other words, the initial margin functions less as a therapeutic boundary and more as a starting point for an iterative process whose endpoint is defined by microscopic confirmation rather than by a measurement taken before the first cut. The safety net of complete margin evaluation means that a conservative starting margin does not translate into a higher risk of leaving disease behind.

The choice of initial margins in Mohs surgery for melanoma has long been both variable and controversial. Many surgeons opt for starting margins of less than one centimeter, reasoning that the technique’s complete margin assessment makes large initial cuffs unnecessary and that smaller initial excisions spare more healthy tissue—a consideration of particular importance on the face, ears, and other cosmetically and functionally sensitive sites where melanomas are common. Others have argued for wider initial margins, extrapolating from guidelines developed for wide local excision, where the margin itself is the primary safeguard against residual disease. The new findings lend support to the former camp, suggesting that conservative starting margins in Mohs surgery do not compromise survival.

The results also align with a broader shift in the evidence base surrounding Mohs surgery for melanoma. A 2022 systematic review and meta-analysis found that local recurrence of melanoma is higher after wide local excision than after Mohs micrographic surgery or staged excision, challenging the assumption that the traditional approach offers superior local control. A 2023 systematic review and meta-analysis focused specifically on margins concluded that disease-specific survival after Mohs surgery is not impacted by initial margin selection, and a separate National Cancer Database analysis published the same year found no survival benefit associated with wide-margin Mohs surgery for melanoma. Studies comparing the two techniques directly have reported that Mohs surgery is associated with excellent efficacy and low recurrence rates, and some database analyses have even suggested improved overall survival for melanomas of the head, neck, trunk, and extremities treated with the Mohs approach compared with wide local excision.

Historically, the use of Mohs micrographic surgery for melanoma was itself contentious, with early guidelines favoring wide local excision as the standard of care for all invasive melanomas. Concerns centered on whether the technical demands of processing melanoma tissue—interpreting atypical melanocytes at margins is more subtle than assessing epithelial cancers such as basal cell or squamous cell carcinoma—could be met reliably. Over time, refinements in technique, including the use of immunohistochemical stains that highlight melanocytes, and accumulating outcome data have eroded that skepticism. A 2021 systematic review catalogued the many technical variations now in use for Mohs surgery for melanoma, and current practice guidelines have evolved to acknowledge the technique’s role, particularly for melanomas arising in anatomically constrained locations where wide excision would cause significant morbidity.

The authors of the new report are careful to note the limitations of their work. The study was retrospective, relying on chart review rather than prospective randomization, which introduces the possibility of unmeasured confounding. The cohort, while sizable for a single institution, was limited in number, and the range of initial margin sizes actually used by surgeons constrained the statistical power to detect small effects. Most importantly, only two melanoma deaths occurred in the entire cohort, which means the analysis rests on an extremely small number of events. A truly definitive answer to the margin question would require a much larger, ideally multi-center or randomized comparison. Nevertheless, the consistency of the finding with prior meta-analytic evidence strengthens the case that initial margin selection is not a survival-critical variable in this setting.

For patients with thin melanomas, the practical implications are encouraging. The study suggests that surgeons using Mohs micrographic surgery can select conservative initial margins without fear of compromising survival, provided the technique’s complete margin evaluation is performed rigorously. Smaller initial excisions mean less tissue removed, smaller defects to reconstruct, and potentially better cosmetic and functional outcomes—benefits that are especially meaningful when melanomas arise on the face and other visible or functionally critical sites. As evidence accumulates that margin selection in Mohs surgery for early melanoma does not affect disease-specific mortality, the conversation among surgeons may shift from how wide to start toward how to optimize the iterative margin-mapping process itself, ensuring that the microscopic certainty that defines the technique remains its true protective power.

Subject of Research: The effect of initial Mohs micrographic surgery margin size on disease-specific mortality in patients with early-stage melanoma.

Article Title: Impact of initial Mohs micrographic surgery margins for melanoma on disease specific mortality

Article References: Cull, D., Campbell, E., Bangalore-Kumar, A., Trischman, T., Asamoah, E., Vidal, N. Y., & Demer, A. (2026). Impact of initial Mohs micrographic surgery margins for melanoma on disease specific mortality. Archives of Dermatological Research, 318(1), Article 453. https://doi.org/10.1007/s00403-026-04904-0

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04904-0

Keywords: Mohs micrographic surgery, melanoma, surgical margins, disease-specific mortality, skin cancer, wide local excision, T1 melanoma, margin control, dermatologic surgery, melanoma survival, recurrence, surgical oncology